Efficacy and safety of bedaquiline and delamanid in the treatment of drug-resistant tuberculosis in adults: A systematic review and meta-analysis

基岩 医学 队列 肺结核 内科学 养生 入射(几何) 队列研究 不利影响 置信区间 结核分枝杆菌 病理 物理 光学
作者
Syeda Hoorulain Ahmed,Hoorain Haider,Abdul Moeed,A. H. Mahmood,Nasir Shivani,Syed Hasan Shuja,Javeria Hayat,Bushra Jamil,Razia Fatima
出处
期刊:The Indian journal of tuberculosis [Elsevier BV]
卷期号:71 (1): 79-88 被引量:5
标识
DOI:10.1016/j.ijtb.2023.05.005
摘要

Multi and extensively drug-resistant tuberculosis is a grave cause of global public health concern due to its high mortality and limited treatment options. We conducted this systemic review and meta-analysis to evaluate the efficacy and safety of bedaquiline and delamanid, which have been added to the WHO-recommended regimen for treating drug-resistant tuberculosis. Electronic databases were searched from their inception until December 1st, 2021, for eligible studies assessing the efficacy and safety of bedaquiline and delamanid for treating drug-resistant tuberculosis. Binary outcomes were pooled using a DerSimonian-Laird random-effects model and arcsine transformation and reported on a log scale with a 95% confidence interval (CIs). Twenty-one studies were shortlisted in which bedaquiline, delamanid, and a combination of both were administered in 2477, 937, and 169 patients. Pooled culture conversion at 6 months was 0.801 (p < 0.001), 0.849 (p = 0.059) for bedaquiline and delamanid, respectively, and 0.823 (p = 0.017), concomitantly. In the bedaquiline cohort, the pooled proportion of all-cause mortality at 6 months was reported as 0.074 (p < 0.001), 0.031 (p = 0.372) in the delamanid cohort, and 0.172 in the combined cohort. The incidence of adverse events in the bedaquiline cohort ranged from 11.1% to 95.2%, from 13.2% to 86.2% in the delamanid cohort, and 92.5% in a study in the combined cohort. The incidence of QTC prolongation reported in each cohort is as follows: bedaquiline 0.163 (p < 0.001), delamanid 0.344 (p = 0.272) and combined 0.340 (p < 0.001). Our review establishes the efficacy of delamanid, bedaquiline, and their combined use in treating drug-resistant tuberculosis with reasonable rates of culture conversion, low mortality rates, and safety of co-administration, as seen with their effect on the QTc interval.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HJJHJH完成签到,获得积分10
2秒前
Bob发布了新的文献求助10
3秒前
4秒前
5秒前
HJJHJH发布了新的文献求助50
6秒前
JW完成签到,获得积分10
6秒前
wanci应助张参采纳,获得10
7秒前
谦让的西装完成签到 ,获得积分10
8秒前
李演员完成签到,获得积分10
9秒前
fei菲飞完成签到,获得积分10
9秒前
11秒前
Zhaowx完成签到,获得积分10
11秒前
Theprisoners完成签到,获得积分0
11秒前
木子发布了新的文献求助30
11秒前
11秒前
下课了吧完成签到,获得积分10
12秒前
丘比特应助xialuoke采纳,获得10
13秒前
zgt01发布了新的文献求助10
15秒前
linfordlu完成签到,获得积分0
15秒前
清浅发布了新的文献求助10
16秒前
风趣的涵柏完成签到,获得积分10
17秒前
19秒前
Chen完成签到 ,获得积分10
20秒前
21秒前
木樨完成签到,获得积分10
22秒前
科研顺利完成签到,获得积分10
23秒前
Bin完成签到,获得积分10
24秒前
gszy1975发布了新的文献求助10
24秒前
十曰发布了新的文献求助10
25秒前
26秒前
26秒前
jiaolulu发布了新的文献求助10
31秒前
畅快的念烟完成签到,获得积分10
33秒前
丽莫莫完成签到,获得积分10
33秒前
钙离子完成签到,获得积分10
34秒前
情怀应助OLDBLOW采纳,获得10
35秒前
潇洒日记本完成签到,获得积分10
36秒前
vsvsgo发布了新的文献求助30
37秒前
量子星尘发布了新的文献求助10
37秒前
xiaodong完成签到,获得积分10
37秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022